CRIS Current Research Information System

RONDONI, MICHELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.276
NA - Nord America 3.113
EU - Europa 3.012
AF - Africa 195
SA - Sud America 192
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 2
Totale 9.806
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.083
IT - Italia 987
CN - Cina 924
SG - Singapore 837
VN - Vietnam 836
GB - Regno Unito 626
SE - Svezia 339
DE - Germania 296
HK - Hong Kong 237
IN - India 141
BR - Brasile 136
UA - Ucraina 123
RU - Federazione Russa 118
JP - Giappone 117
NL - Olanda 105
FR - Francia 103
KR - Corea 100
IE - Irlanda 81
CI - Costa d'Avorio 69
TG - Togo 54
FI - Finlandia 48
ZA - Sudafrica 45
EE - Estonia 40
CH - Svizzera 30
AR - Argentina 24
JO - Giordania 21
BG - Bulgaria 20
CA - Canada 19
PL - Polonia 18
BE - Belgio 17
ES - Italia 16
ID - Indonesia 16
EU - Europa 15
SC - Seychelles 14
GR - Grecia 13
EC - Ecuador 11
IR - Iran 10
BD - Bangladesh 9
MX - Messico 8
AT - Austria 7
NG - Nigeria 6
PY - Paraguay 6
RO - Romania 6
TR - Turchia 6
CL - Cile 5
LB - Libano 4
MY - Malesia 4
PT - Portogallo 4
AE - Emirati Arabi Uniti 3
BY - Bielorussia 3
CZ - Repubblica Ceca 3
IQ - Iraq 3
LT - Lituania 3
VE - Venezuela 3
BA - Bosnia-Erzegovina 2
CO - Colombia 2
CR - Costa Rica 2
IL - Israele 2
NE - Niger 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PE - Perù 2
SA - Arabia Saudita 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BF - Burkina Faso 1
BO - Bolivia 1
DM - Dominica 1
EG - Egitto 1
GY - Guiana 1
KE - Kenya 1
KZ - Kazakistan 1
MR - Mauritania 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 9.806
Salva come PNG Salva come JPEG
Città #
Southend 557
Singapore 547
Fairfield 309
Ashburn 307
Chandler 288
Hefei 248
Hong Kong 235
Ho Chi Minh City 208
Wilmington 168
Hanoi 163
Houston 159
Woodbridge 150
Seattle 143
Dong Ket 130
Cambridge 122
Beijing 121
Ann Arbor 120
Santa Clara 109
Tokyo 108
Princeton 105
Seoul 98
Bologna 87
Milan 86
Dallas 81
Boardman 80
Dublin 80
Jacksonville 80
Abidjan 69
Florence 64
Padova 56
Lomé 54
Los Angeles 54
Westminster 50
Nanjing 49
Turin 49
New York 43
Rome 42
Saint Petersburg 32
Helsinki 31
Berlin 27
Shenyang 27
Haiphong 26
Jinan 25
Buffalo 24
Munich 24
Bern 23
Amman 21
Bengaluru 21
Redondo Beach 21
Ha Long 20
Nanchang 20
Hebei 19
Medford 19
Naples 18
San Diego 18
Sofia 18
Biên Hòa 17
Bremen 17
Pavia 17
Changsha 16
Da Nang 15
Falls Church 15
Frankfurt am Main 15
Zhengzhou 15
Brussels 14
Redmond 14
Warsaw 14
Jiaxing 13
Orem 13
Shanghai 13
Thái Nguyên 13
Haikou 12
São Paulo 12
Mülheim 11
Norwalk 11
Toronto 11
Vũng Tàu 11
Catania 10
Düsseldorf 10
Ninh Bình 10
Palermo 10
Pescara 10
Quận Bình Thạnh 10
Verona 10
Hải Dương 9
Mahé 9
Mountain View 9
Nuremberg 9
Tianjin 9
Turku 9
Brescia 8
Chicago 8
Falkenstein 8
Guangzhou 8
Ningbo 8
Olalla 8
Brasília 7
Brooklyn 7
Can Tho 7
Harbin 7
Totale 6.342
Salva come PNG Salva come JPEG
Nome #
Instillazione diretta intranasale di amfotericina B liposomiale nella terapia delle micosi nasali. 731
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 627
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 269
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 258
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 208
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 199
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 198
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. 196
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 191
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 184
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 170
Prompt resolution of nasal aspergillosis with intranasal instillation of liposomal amphotericin-B (amBisome) and granulocyte transfusions 167
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 166
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 164
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 160
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 157
Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. 155
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL 155
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia 155
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents 153
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 152
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 148
Advanced mast cell disease: an Italian Hematological Multicenter experience 145
Leucemia mieloide cronica: terapia molecolare 142
Ultra-Deep Sequencing (UDS) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 139
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients 138
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis 136
Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely. 134
Polo-like Kinase-1 and Aurora Kinase A As Novel Therapeutic Targets in Neoplastic Mast Cells 134
Exploring the role of PARP1 inhibition in enhancing antibody–drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions 132
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study. 132
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 132
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia 129
PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment. 127
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 127
WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. 125
Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients 122
Novel insights and therapeutic approaches in secondary AML 121
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis 121
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications 119
High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL) 118
Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid Leukemia 116
Soft tissue and skeletal involvement in FIP1L1-PDGFR-A positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission 115
Imatinib mesylate in the treatment of hematologic malignancies. 114
Hypereosinophilic syndrome and molecularly targeted therapy. 113
Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL). 112
Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. 111
Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene 109
Serum total tryptase level confirms itself as a more reliable marker of mast cells burden in mast cell leukaemia (aleukaemic variant) 108
The Overexpression of Spliced Oncogenic Ikaros Isoforms in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Is a New Mechanism of Resistance to Tyrosine Kinase Inhibitors. 108
HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING IDENTIFIES NOVEL UNIPARENTAL DISOMY AND FOCAL COPY NUMBER ALTERATIONS IN ACUTE PROMYELOCYTIC LEUKEMIA (APL) 105
New Horizons in Immunology and Immunotherapy of Acute Leukemias and Related Disorders 104
null 104
Acute Myeloid Leukemia: Updates on Diagnosis, Treatment and Management 103
The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. 93
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM Experience 89
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain 89
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly 89
Low WT1 Expression Identifies a Subset of Acute Myeloid Leukemia with a Distinct Genotype 86
Long-term molecular complete remission with IFN-alpha in Ph+ adult acute lymphoid leukemia patients. 85
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis 85
Strategies in the treatment of acute myeloid leukemia. 83
null 76
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. 70
PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study 67
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a 61
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC 54
Rearrangements of ATP5L‐KMT2A in acute lymphoblastic leukaemia 52
Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series 30
The Italian Mastocytosis Registry: 6-year experience from a Hospital-Based Registry 27
Matching-adjusted indirect comparison of CPX- 351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life study 9
Totale 10.003
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.987
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.987
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021521 0 0 0 0 0 66 20 37 71 54 37 236
2021/20221.006 94 17 63 117 94 84 17 66 37 75 187 155
2022/20231.365 160 233 52 173 66 96 50 65 224 28 171 47
2023/2024548 29 63 37 42 44 126 43 60 23 26 28 27
2024/20251.634 64 221 120 108 204 84 185 69 27 148 100 304
2025/20262.586 393 911 387 314 393 188 0 0 0 0 0 0
Totale 10.003